Kunming Sinoway Natural Pharmaceuticals Co., Ltd. was founded in 1998 and is a high-tech pharmaceutical enterprise integrating the research and development, production, and sales of chemical preparations, traditional Chinese medicines, and biopharmaceuticals. It was invested in and acquired by Sinoway Investment Corporation in 1998 and has gradually developed into a modern pharmaceutical company specializing in macromolecular biologics and chemical drugs.

Sinoway Pharmaceutical’s core therapeutic areas include cardiovascular and cerebrovascular diseases, digestive system disorders and wound repair, anti-hepatitis B antiviral treatments, orthopedics and trauma, as well as topical medications. Its representative products include Kangfuxin Ye (Rehabilitation New Liquid, a nationally protected traditional Chinese medicine), Ganlong Capsules (a national Class II new drug), Xinluoping (an innovative antihypertensive drug), Yimaikang Tablets, Xibi Yi (a patented nasal wash product), Ningxinbao (Cordyceps sinensis refined capsules), and others.

With its core competitiveness centered on distinctive traditional Chinese medicine combined with innovative R&D, Sinoway Pharmaceutical is developing toward large-scale and innovation-driven growth, aiming to become a representative biopharmaceutical enterprise in Yunnan.